Literature DB >> 22961158

The tumor microenvironment controls drug sensitivity.

Arne Ostman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22961158     DOI： 10.1038/nm.2938

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  18 in total

1.  The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin.

Authors:  Osvaldo Pontiggia; Rocio Sampayo; Diego Raffo; Andrea Motter; Ren Xu; Mina J Bissell; Elisa Bal de Kier Joffé; Marina Simian
Journal:  Breast Cancer Res Treat       Date:  2011-09-21       Impact factor: 4.872

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

4.  Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.

Authors:  Ubaldo E Martinez-Outschoorn; Allison Goldberg; Zhao Lin; Ying-Hui Ko; Neal Flomenberg; Chenguang Wang; Stephanos Pavlides; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

5.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

Authors:  Linda Sofie Lindström; Eva Karlsson; Ulla M Wilking; Ulla Johansson; Johan Hartman; Elisabet Kerstin Lidbrink; Thomas Hatschek; Lambert Skoog; Jonas Bergh
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

6.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

7.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

Authors:  Elizabeth S Nakasone; Hanne A Askautrud; Tim Kees; Jae-Hyun Park; Vicki Plaks; Andrew J Ewald; Miriam Fein; Morten G Rasch; Ying-Xim Tan; Jing Qiu; Juwon Park; Pranay Sinha; Mina J Bissell; Eirik Frengen; Zena Werb; Mikala Egeblad
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

8.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

9.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authors:  Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

10.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962
View more
  46 in total

1.  Microfluidic platform for the study of intercellular communication via soluble factor-cell and cell-cell paracrine signaling.

Authors:  Matthew B Byrne; Lisa Trump; Amit V Desai; Lawrence B Schook; H Rex Gaskins; Paul J A Kenis
Journal:  Biomicrofluidics       Date:  2014-07-10       Impact factor: 2.800

2.  Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells.

Authors:  Emarndeena H Cheteh; Victoria Sarne; Sophia Ceder; Julie Bianchi; Martin Augsten; Helene Rundqvist; Lars Egevad; Arne Östman; Klas G Wiman
Journal:  Cell Death Discov       Date:  2020-06-02

Review 3.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

4.  The potential of heparanase as a therapeutic target in cancer.

Authors:  Claudio Pisano; Israel Vlodavsky; Neta Ilan; Franco Zunino
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

Review 5.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

6.  CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages.

Authors:  Jia-Bin Wang; You-Xin Gao; Yin-Hua Ye; Tong-Xing Lin; Ping Li; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Ju-Li Lin; Ze-Ning Huang; Hua-Long Zheng; Jian-Wei Xie; Chao-Hui Zheng; Chang-Ming Huang
Journal:  Cancer Gene Ther       Date:  2022-08-23       Impact factor: 5.854

7.  Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer.

Authors:  Weicai Huang; Yuming Jiang; Wenjun Xiong; Zepang Sun; Chuanli Chen; Qingyu Yuan; Kangneng Zhou; Zhen Han; Hao Feng; Hao Chen; Xiaokun Liang; Shitong Yu; Yanfeng Hu; Jiang Yu; Yan Chen; Liying Zhao; Hao Liu; Zhiwei Zhou; Wei Wang; Wei Wang; Yikai Xu; Guoxin Li
Journal:  Nat Commun       Date:  2022-08-30       Impact factor: 17.694

8.  Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

Authors:  Hanyin Cheng; Mizue Terai; Ken Kageyama; Shinji Ozaki; Peter A McCue; Takami Sato; Andrew E Aplin
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

9.  Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.

Authors:  Jielin Li; Laura Pohl; Julia Schüler; Nina Korzeniewski; Philipp Reimold; Adam Kaczorowski; Weibin Hou; Stefanie Zschäbitz; Cathleen Nientiedt; Dirk Jäger; Markus Hohenfellner; Anette Duensing; Stefan Duensing
Journal:  Biomedicines       Date:  2021-05-31

10.  Evaluation of nanoparticle uptake in co-culture cancer models.

Authors:  Elisabete C Costa; Vítor M Gaspar; João G Marques; Paula Coutinho; Ilídio J Correia
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.